Since 2018, the TAILORx and RxPONDER trials have demonstrated that the 21-gene recurrence score (RS) can be indicative of the benefit of adjuvant chemotherapy in hormone receptor (HR)–positive, ERBB2 (formerly HER2)–negative breast cancer with 3 or fewer positive lymph nodes. Here, NR4A1 is linked to breast carcinoma.